FDA Early Alert: ButterflyBVM Bag-Valve-Mask Corrugated Bags May Develop Holes; 31 Lots Split into Removal and Correction Actions

FDA Early Alert: ButterflyBVM Bag-Valve-Mask Corrugated Bags May Develop Holes; 31 Lots Split into Two Actions

On November 3, 2026, the U.S. Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH) updated its public Early Alert page concerning Compact Medical's actions for certain lots of the ButterflyBVM disposable bag-valve-mask resuscitator. The alert divides the same product line into two action categories: some lots must be removed from use and sale locations, while other lots may remain in use only if an updated pre-use test is performed.

Company timeline

The company timeline is stated on the official page. On September 26, 2026, Compact Medical sent a customer letter explaining that, in a small number of cases, the corrugated bag may develop holes. On October 7, 2026, the company sent a follow-up letter to all affected customers, defining the actions as removal and correction and listing the lots item by item.

Nine lots subject to removal

The removal scope is described as covering three models. The product identifiers expressly listed in the alert are the standard ButterflyBVM (single SKU A100, case A108, unit UDI-DI 00860012073504) and the READY model (single SKU R300, case R308, unit UDI-DI 00860012073528 and 00860012073573). The nine lots on the removal list are 000109, 000110, 000111, 000112, 000113, 000114, 000115, 000116 and 000117.

The official determination for these lots is do not use, with an explicit sequence: first place replacement products in position, then locate and remove the affected devices from vehicles, crash carts, sites and warehouses one by one. The reason is that emergency care settings cannot have an empty slot; the removal action itself must not create a gap in which no bag-valve-mask is available.

Twenty-two lots subject only to correction

The second category contains more lots and involves the READY, standard and PLUS models (single SKU P200, case P208, unit UDI-DI 00860012073511). The READY lots are 000081, 000083, 000084, 000086, 000093, 000094, 000097, 000098, 000099, 000100, 000101, 000104, 000107 and 000108. The standard lots are 000090, 000091, 000096 and 000105. The PLUS lots are 000089, 000092, 000095 and 000106. The total is 22 lots.

These products do not need to be taken out of service, but the conditions are specific: before each use on a patient, the pre-use test or device check section of the instructions must be completed, and any device that fails the check must not be used on a patient. Each device must also have a usable backup bag-valve-mask available in case the on-site test fails.

Why a hole in the corrugated bag is considered a potential high risk

The mechanism described by the FDA is straightforward. If a hole forms in the corrugated bag, the set tidal volume leaks into the environment rather than entering the patient's lungs, resulting in under-ventilation and then hypoxemia. In emergency settings, this type of failure is difficult to identify immediately. The operator may see only reduced chest rise or falling oxygen saturation readings and may first adjust routine parameters, while the true cause is the device itself.

The page also sets the current information boundary: as of November 2, 2026, the company had not reported serious injury or death related to the issue, and the FDA is still reviewing the relevant information, with the page to be updated as new information becomes available. In other words, the risk is a potential high risk, not an injury statistics already realized.

The most common field error

The FDA specifically states that if the device packaging and labels are no longer available, the device should be assumed to be within the affected lot range. This places the burden of proof on the user: inability to identify the lot does not mean the device can be ignored; if the lot cannot be identified, it should be handled as within scope.

Other actions include: quarantine the device and mark it DO NOT USE with a permanent marker; distributors should stop distribution of lots 000109 through 000117; any single device that failed in use or is associated with patient harm must not be destroyed, and must be retained with its original packaging, isolated, and the company contacted for further instructions. If poor chest rise or falling oxygen saturation is observed during use, first confirm whether there is a hole in the back of the device. If a hole is confirmed, immediately replace the device with a backup, then mark, isolate and contact the company in that order.

An Early Alert is not a recall classification

This notice appears under CDRH's Early Alert section. The section was launched as a pilot on November 21, 2024, and was expanded to all medical devices on September 29, 2025. The FDA defines it as follows: the company has already implemented a removal, correction or update to instructions for use, and the FDA believes these actions are likely to meet the most serious recall classification, but the agency has not yet determined that they meet the regulatory definition of a recall.

For companies, this difference affects timing rather than obligations. Early Alerts often appear before the recall database is formally established and classified. They are published earlier and spread faster, and customers and distributors will immediately ask for handling plans when they see them. Waiting for the classification before preparing a response is usually too late.

AIMEILI Regulatory Interpretation

This case is a practical example of how FDA Early Alerts function as an early transparency and action signal rather than a final recall classification. The absence of a recall class does not reduce the need for manufacturers and distributors to act. The two-tier structure of removal and correction should be read as a field-action strategy that matches risk control to lot-level evidence.

• Removal is not a simple withdrawal. The FDA explicitly requires replacements to be in place before affected units are removed. In emergency care, a device gap can itself create patient risk. Field-action procedures should therefore include replacement logistics, not only retrieval instructions.
• Correction depends on executable pre-use testing. Keeping 22 lots in clinical use is conditional on a pre-use test or device check before every patient use and on backup devices being available. If a customer cannot reliably implement these conditions, continued use is difficult to justify.
• Lot traceability determines the size of the action. The ability to narrow the action to 31 lots across multiple UDI-DIs depends on production records matching distribution records. Where lot-level traceability is incomplete, a broader model-level action may be the only defensible approach.
• The missing-label rule shifts the burden to users. If packaging and labels are unavailable, the device should be treated as affected. Manufacturers and distributors should plan inventory reconciliation and customer instructions around this assumption.
• Common-platform risk must be assessed across models. The standard, READY and PLUS models share the corrugated bag structure, so a risk assessment limited to one SKU's sales data may be incomplete.
• Failed or harm-associated devices should be preserved. Devices that failed in use or are associated with patient harm should not be destroyed. Retaining original packaging, isolating the device and contacting the company are important for subsequent investigation and regulatory review.

Business Impact for Global Stakeholders

For manufacturers, the immediate impact is a lot-level field action that requires coordinated customer notification, inventory recovery, replacement planning, distributor instructions and updated training on pre-use checks. The September 26 and October 7, 2026, letters show that customer communication may begin well before FDA assigns a recall classification. Regulatory affairs teams should prepare holding statements, customer FAQs and distributor scripts in parallel with the investigation.

For distributors and hospital customers, the operational priority is to separate the nine removal lots from the 22 correction lots, stop distribution of lots 000109 through 000117, quarantine affected stock and ensure that replacement devices are in place before removal from vehicles, crash carts and emergency sites. For the correction lots, the practical priority is to confirm that every device has a usable backup and that pre-use testing is actually performed before patient use.

For CROs and regulatory affairs teams supporting global device companies, this alert illustrates why post-market surveillance should monitor FDA Early Alerts alongside recall databases. Early Alerts can trigger customer and distributor questions before a formal recall classification exists. A response prepared only after classification may be too late for commercial and clinical relationships.

For exporting manufacturers, the case reinforces three operational lessons. First, precise lot definition directly controls field-action cost. Second, pre-use testing must be written into the instructions for use and must be executable by users. Third, different models on the same platform should be assessed together when a shared component is implicated.

Sources and Verification Notes

Source: U.S. Food and Drug Administration (FDA), CDRH — Early Alert: Compact Medical Removes and Updates Use Instructions for ButterflyBVM Bag-Valve-Mask Resuscitators. Page content updated November 3, 2026.

https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/early-alert-compact-medical-removes-and-updates-use-instructions-butterflybvm-bag-valve-mask

Source: U.S. Food and Drug Administration (FDA), CDRH — What is an Early Alert? Page content updated September 29, 2025.

https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/what-early-alert

Source: U.S. Food and Drug Administration (FDA), CDRH — Medical Device Recalls and Early Alerts list page, used to verify the publication date of November 3, 2026 for this alert.

https://www.fda.gov/medical-devices/medical-device-safety

Verification scope and access date: the three official FDA pages above were reviewed, and the affected product table (model, SKU, UDI-DI and lot), the boundary between the two action categories, the company letter dates of September 26 and October 7, 2026, the risk description and the statement that no serious injury or death had been reported as of November 2, 2026 were compared item by item. The access date was November 4, 2026. The full text of the company announcement, the specific inspection steps in the instructions for use and any subsequent recall classification were outside the scope of this verification.

Applicability note: this article summarizes and interprets public FDA regulatory information and does not constitute a compliance conclusion or commitment for any specific product, company or registration application. Lot scope, action requirements and risk descriptions are subject to the official FDA page and may change with subsequent official updates. For specific products on the market, the official original text and the latest version of the instructions for use should be the final basis.